CCG
AZN icon

Cypress Capital Group’s AstraZeneca AZN Stock Holding History

Cypress Capital Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,325
Closed -$206K – 258
2024
Q3 		$206K Buy
+1,325
New +$214K 0.02% 304

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Cypress Capital Group's AZN Position: Q4 2024 in Review

Cypress Capital Group sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 1,325 shares — an estimated $206K sold.

Cypress Capital Group first reported a position in AZN in Q3 2024 and held it in 1 quarter. The position peaked at $206K in Q3 2024. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Cypress Capital Group reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Cypress Capital Group sold 1,325 AstraZeneca shares in Q4 2024, an estimated $206K.
  • Cypress Capital Group first reported a position in AstraZeneca in Q3 2024 and held it in 1 quarter.
  • Cypress Capital Group's AstraZeneca position peaked at $206K in Q3 2024.
  • 1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Cypress Capital Group's 13F filing for Q4 2024, filed 6 Feb 2025.